Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2015) 37 EP145 | DOI: 10.1530/endoabs.37.EP145

ECE2015 Eposter Presentations Reproduction, endocrine disruptors and signalling (92 abstracts)

Analysing by decade, testosterone undecanoate depot injectable does not increase prostate volume: study during up to 7 years on hypogonadic patients

Matei Pisoschi 1 , Mara Carsote 2 , Catalina Poiana 2 , Dana Cristina Staicu 3 & Dan Peretianu 3


1Hospital ‘Th. Burghele’, Bucharest, Romania; 2Institute of Endocrinology, Bucharest, Romania; 3Societatea Civila Medicala ‘Povernei’, Bucharest, Romania.


Aim: Re-analysing the effect of injectable testosterone undecanoate depot (TUD) in hypogonadic patients.

Materials and method: (A) Patients: at onset 210 men with hypogonadism (median age: 61.5 years). (B) Distribution: by decade; n=4, 12, 21, 54, 59, 43, 16, and 1. (C) TUD (NebidoR-Bayer-Schering) 1000 mg was injected one per 3 months i.m. (D) Prostate volume (PV) appreciated by per-abdominal ultrasound: 3.5 MHz probe, elliptical volume (cm3), Aloka 550. (E) Time of analysis: before starting testosterone (T0), after ½ month (T1), 3 months (T2), 6 months (T3), 1 year (T4), 2 years (T5), 3 years (T6), 4 years (T7), 5 years (T8, n=28), 6 years (T9, n=12), and 7 years (T10, n=6). (F) Maximum increment from T0 was noted Δ M %. Average increment was noted A %. (G) Statistical analysis: Student’ t-test.

Results: i) All average prostatic volume for decade in figure. Maximum increment (Δ M %) per decade (45.95; 20; 40.35; 42.5; 45.45; 64.41; and 39.56), including the moment (Δ M % at) and average increment (Δ A %) (Table). (II) PV at T0 increases with age, from minimum 15.38 (19–29 years) to maximum 47.41 (80–89 years), P=0.0007. (III) Considering all observations (some at 5/6/7 years), TUD did not increase PV significantly (in fact the average of increment in all patients was negative=−12.54%). Δ M % per decade: 20. (IV) Inside a specific decade no significant increase in PV was registered: all P>0.05; exception: 80–89 decade, P=0.002, at 3–5 years. (V) In some patients, especially from 50 to 79 years, TUD could decrease slightly prostatic volume.

Conclusions: Considering the risk for prostate (in elderly), testosterone undecanoate 1000 mg depot injectable is a safe treatment, even after 3–7 years of administration. Precautions should be accorded to men over 80 years old, after the 3rd year administration.

Article tools

My recent searches

No recent searches.